Author(s): Amol K Choulwar, Ashish A. Mungantiwar, Meena Chintamaneni

Email(s): achoulwar@macleodspharma.com

DOI: Not Available

Address: Amol K Choulwar, Ashish A. Mungantiwar, Meena Chintamaneni
R & D Center, Macleods Pharmaceuticals Ltd, G-2, Mahakali Caves Road, Shanti Nagar, Andheri-East. Mumbai-400093, Maharashtra, India.
School of Pharmacy and Technology Management, Narsee Monjee Institute of Management & Higher Studies, Vile Parle (West), Mumbai – 400 056, Maharashtra, India
*Corresponding Author

Published In:   Volume - 5,      Issue - 5,     Year - 2012


ABSTRACT:
This paper is an attempt to compare the bioavailability of two Ivabradine tablet formulations (test and reference) containing 7.5mg mg of Ivabradine. The bioequivalence of two formulations (test and reference) was determined in 12 healthy Indian male volunteers (age: 25.25 +/- 4.69 years; weight: 60.50 +/- 5.04 kg) in An open label, balanced, analyst blind, randomized, two-treatment, two-period, two sequence, single dose, crossover study. Both formulations were administered orally as a single dose. Ivabradine plasma levels were determined by a validated LC-MS/MS method. The formulations were compared using the pharmacokinetic parameters peak plasma concentration (Cmax), time to reach maximum concentration (T(max)), area under the plasma concentration-time curve (AUC(0-t)), area under the plasma concentration-time curve from zero to infinity (AUC(0-infinity)) and elimination half-life (t(1/2)) were 41.899 ± 18.7472 and 39.392 ± 10.5835 ng/mL, 1.229 ± 0.5786 and 0.958 ± 0.4626 h, 142.611 ± 57.3519 and 146.245 ± 52.9796 ng x hr/ml, 148.937 ± 57.2911and 153.723 ± 53.6352 ng x hr/ml, and 2.182 ± 0.3520 and 2.282 ± 0.4536 hr for the test and reference formulation, respectively. The 90% confidence intervals on the mean of the difference (test - reference) between log-transformed values of the two formulations were 88.40% to 117.32%, 85.13% to 109.74%, and 85.44% to 108.19% for C(max), AUC(0-t) and AUC(0-infinity) respectively. In conclusion, the test formulation is bioequivalent to the reference in terms of both the rate and extent of absorption. Both the formulations are well tolerated and no serious clinical adverse events causing death, disability, hospitalization, or dropouts of the subjects were encountered following a single dose administration of the investigational product.


Cite this article:
Amol K Choulwar, Ashish A. Mungantiwar, Meena Chintamaneni. A comparative, Bioequivalence study to evaluate the safety and pharmacokinetic profile of single dose Ivabradine 7.5mg Tablets in healthy, adult, human subjects under fasting condition. Research J. Pharm. and Tech. 5(5): May2012; Page 658-666.

Cite(Electronic):
Amol K Choulwar, Ashish A. Mungantiwar, Meena Chintamaneni. A comparative, Bioequivalence study to evaluate the safety and pharmacokinetic profile of single dose Ivabradine 7.5mg Tablets in healthy, adult, human subjects under fasting condition. Research J. Pharm. and Tech. 5(5): May2012; Page 658-666.   Available on: https://www.rjptonline.org/AbstractView.aspx?PID=2012-5-5-5


Recomonded Articles:

Research Journal of Pharmacy and Technology (RJPT) is an international, peer-reviewed, multidisciplinary journal.... Read more >>>

RNI: CHHENG00387/33/1/2008-TC                     
DOI: 10.5958/0974-360X 

0.38
2018CiteScore
 
56th percentile
Powered by  Scopus


SCImago Journal & Country Rank


Recent Articles




Tags


Not Available